CD8A and neoplasm: For example, mutations in β‐2 microglobulin (β‐2M) on cancer cell surfaces can result in the loss of HLA‐1 expression, preventing the effective presentation of tumor antigens on the cell surface, thereby hindering CD8+ T cell recognition [80].